Latest / Speaking of Supply Chain
Why Pharma Cannot React Its Way Out of the Next Crisis
Risk used to be something pharmaceutical companies responded to. Now it is something they have to design for.
For decades, pharma optimized for scale and cost. APIs and starting materials moved to India and China, manufacturing capabilities in Europe quietly disappeared, and intense price pressure became the unquestioned baseline. Then came the Suez blockage, COVID, tariffs, and conflict-driven disruptions. Each one was treated as a singular event to react to, not as a signal that the underlying network itself needed to change.
In this episode, Ellen Wood is joined by Stephan Gotthardt, fresh…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.